TEST ALTRADX
Molecular diagnosis of thyroid nodules
ALTRADX complements initial tests and improves the accuracy of malignancy risk assessment.
Includes:
- microRNA profile.
- Mutations associated with thyroid cancer (BRAF, TERT).
- Markers associated with tumor aggressiveness.
Evaluation of Thyroid Nodules
Up to 60% of people will develop thyroid nodules at some point.
The limited number of initial studies does not allow for a clear assessment of the risk.
These cases may lead to surgery even without confirmation of malignancy.
Up to 60% of people will develop thyroid nodules at some point.
The limited number of initial studies does not allow for a clear assessment of the risk.
These cases may lead to surgery even without confirmation of malignancy.
Test performance
ALTRADX has demonstrated a high negative predictive value (96%), meaning that a negative result is associated with a very low probability of malignancy.
In addition, it has a positive predictive value of approximately 76%, which allows for more accurate identification of high-risk cases.
In clinical practice, its use has been associated with an approximate 75% reduction in unnecessary surgeries and has influenced medical decision-making in about 92% of cases.
Review the clinical evidence, methodology, and
applications of the Test ALTRADX in the full brochure.
Would you like to schedule an appointment or ask questions?
Leave us your details and we will contact you shortly.